News Hub | News Direct

Evgen Pharma "delighted" with cash position after promising first half

Evgen Pharma PLC

Evgen Pharma PLC (AIM:EVG) CEO Dr Huw Jones and new CFO Toni Hanninen speak to Thomas Warner from Proactive after the clinical stage drug development company announced its interim results for the six months to 31 September 2023. Dr Jones gives an overview of how Evgen has been performing on the operational side, highlighting clinical progress, the successful receipt of some new grant funding as well as changes to the board and to the executive team with the hiring of Toni Hanninen in late summer. Hanninen gives an overview of how Evgen performed financial during the reporting period, noting that there were no nasty surprises during the six months and that the company's cash runway of £3.7mln currently runs to the end of 2024. He goes on to say that he is "very very delighted" with the length of the runway given the financial challenges many of Evgen's peers are currently facing. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 31, 2023 06:43 AM Eastern Daylight Time

Video

News Release

Medicus Pharma CEO rings opening bell at the Toronto Stock Exchange

Medicus Pharma

Medicus Pharma executive chairman and CEO Dr Raza Bokhari joined Steve Darling from Proactive fresh from ringing the opening bell at the Toronto Stock Exchange. This after the company recently listed its common shares on the TSX Venture exchange under the ticker MDCX. Medicus Pharma is dedicated to accelerating novel life sciences and biotechnology companies by advancing them through FDA-approved clinical trials. The company specializes in de-risking clinical-stage assets through clinical development and eventual commercialization. Medicus Pharma has a subsidiary called Skinject, which is focused on commercializing a novel, non-invasive treatment for basal cell and squamous cell skin cancer. Skinject employs a patented dissolvable microneedle patch to deliver a chemotherapeutic agent that targets and eradicates tumor cells effectively. The company recently welcomed Dr Huma Qamar as its chief scientific officer and head of R&D Program. Dr Qamar brings a wealth of experience in the clinical research field, having worked with prestigious institutions such as Yale University, Harvard University, and the University of Pennsylvania. Medicus Pharma's listing on the TSX Venture Exchange represents a significant step forward for the company as it continues its mission to advance innovative therapies and treatments in the field of life sciences and biotechnology. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:31 PM Eastern Daylight Time

Video

News Release

Marizyme Inc CEO releases corporate update including details of key progress on DuraGraft

Marizyme Inc

Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for its groundbreaking product, DuraGraft. DuraGraft is a first-in-class vascular conduit solution that has received FDA clearance, marking a significant milestone for Marizyme. This innovative product is specifically indicated for use in adult patients undergoing Coronary Artery Bypass Grafting (CABG) surgeries. Its primary purpose is to facilitate the flushing and storage of saphenous vein grafts employed in CABG procedures, offering a cutting-edge solution to enhance patient outcomes in cardiac surgery. One notable aspect of Marizyme's progress is the growing acceptance of DuraGraft in both Europe and Asia. The company has achieved impressive sales figures, with a total of 1,131 DuraGraft kits shipped so far this year. This is a remarkable increase compared to the 485 DuraGraft kits shipped in the previous year, underscoring the product's traction and demand in the international market. In summary, Marizyme, under the leadership of CEO David Barthel, is making significant strides in the medical industry. The FDA approval of DuraGraft and its increasing adoption in international markets signify the company's commitment to advancing medical technologies that improve patient outcomes. As Marizyme continues to expand its reach and forge new partnerships, it is poised for continued growth and success in the years ahead. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:23 PM Eastern Daylight Time

Video

News Release

BioHarvest Sciences closes first tranche of financing bringing in C$11.78M to Treasury

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share some exciting developments. The company has achieved a major milestone by successfully closing the first tranche of its financing, raising nearly C$12 million, even in the face of challenging market conditions. This accomplishment underscores the significant investor confidence in BioHarvest's strategic vision and the strength of its management team. The capital raised through this financing round will play a pivotal role in advancing several key initiatives within BioHarvest Sciences. One of the notable areas of focus is new product development and expansion. BioHarvest has ambitious plans to expand its product range, moving from a single SKU to ten SKUs spanning five different categories. Leveraging its advanced scientific capabilities, proven efficacy, and exceptional taste, the company is poised to make a significant impact in these markets. The eagerly awaited flagship product, a revolutionary coffee offering, is slated to disrupt the market starting in December. Geographical expansion is another crucial aspect of BioHarvest's growth strategy. With recent approval from Health Canada, the company is gearing up to enter the Canadian market, further extending its global footprint. Additionally, BioHarvest is accelerating clinical trials across various domains, positioning itself for substantial growth over the next 12 to 24 months. These clinical trials will not only underscore the efficacy of their products but also enhance their credibility and market presence. Despite the challenges posed by the current market conditions, BioHarvest remains unwavering in its commitment to the safety of its employees and the consistent delivery of high-quality products. The company's focus for the remainder of 2023 includes robust marketing initiatives and the highly anticipated launch of its innovative coffee product, aimed at revitalizing the stagnant decaffeinated coffee market. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:18 PM Eastern Daylight Time

Video

News Release

1606 Corp announces cutting-edge AI-driven ChatCBDW will launch on Tuesday

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to unveil some thrilling news: the impending launch of its cutting-edge AI chatbot, ChatCBDW. With ChatCBDW currently undergoing final testing phases, the countdown to its official launch is well underway. Lambrecht eagerly shared with Proactive the multifaceted capabilities that ChatCBDW is poised to bring to its users. This AI chatbot has been meticulously designed to offer a diverse range of user-centric features that go beyond the ordinary. Among its standout attributes are its ability to respond to user queries and provide comprehensive education on all aspects of CBD. But ChatCBDW doesn't stop there; it takes personalization to the next level by offering tailored product recommendations to users and engaging in conversations that closely mimic human interaction. This innovation empowers customers to make well-informed choices, explore a wide array of CBD products, and promises an unparalleled shopping experience in the CBD space. At the core of ChatCBDW's prowess is its seamless integration with Microsoft Azure, a platform renowned for its scalability, unwavering reliability, and cutting-edge AI functionalities. This integration ensures that ChatCBDW can operate impeccably, even during peak demand periods, guaranteeing users a consistently responsive and seamless experience throughout their interaction with the chatbot. Notably, 1606 Corp proudly retains 100% ownership of ChatCBDW's intellectual property, demonstrating its commitment to maintaining control over this groundbreaking technology. This ownership provides the company with the flexibility to continually enhance and adapt ChatCBDW to meet the ever-evolving needs of its users and partners across various industries. It signifies 1606 Corp's dedication to staying at the forefront of innovation in the field of AI-driven customer engagement and CBD product discovery. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 02:16 PM Eastern Daylight Time

Video

News Release

BioVie CEO reveals stunning results in Alzheimer's and Parkinson's drug trial

BioVie Inc

BioVie Inc CEO Cuong Do joined Steve Darling from Proactive to share news the company will be presenting its blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s Disease. The presentation will be presented at the upcoming 16th Clinical Trials on Alzheimer's Disease in Boston. Do told Proactive the company has monitored blinded data as they become available throughout the trial to assess patient safety and support timely data entry into the official statistical analysis database. Interim blinded data was previously presented at other scientific congresses to provide a glimpse of the characteristics of the enrolled subjects at the start of the trial. The most surprising revelation was the reduction in amyloid burden. NE3107, designed to block TNF alpha, demonstrated a substantial reduction in amyloid buildup within just six months of treatment. More than a third of initially amyloid-positive patients became amyloid-negative, a highly unexpected outcome. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

October 30, 2023 01:00 PM Eastern Daylight Time

Video

Majority of medical and nursing students planning careers outside patient care as fears of burnout and staff shortages leave them worried about the future

Elsevier

Elsevier Health’s first global “Clinician of the Future 2023: Education Edition” highlights students’ deep concerns about balancing their commitment to patient care with their own well-being. The report also identifies key insights into students’ excitement and fears towards technology and AI in healthcare education Today, Elsevier Health, a global leader in evidence-based clinical practice content, research publishing and information analytics, releases its Clinician of the Future 2023: Education Edition, providing unparalleled insights into the experiences of medical and nursing students and the consequences for the NHS and educators in the UK. The report reveals how the challenges of being a frontline health professional today are impacting the longer-term career decisions of students, highlighting increasingly challenging times ahead for an already overburdened healthcare system. Although almost 9 out of 10 medical and nursing students in the UK feel devoted to improving patients’ lives, findings reveal that 58% already see their current studies as a steppingstone towards a broader career in healthcare that will not involve directly caring for patients. The Clinician of the Future 2023: Education Edition presents a worrying snapshot of the pressures that medical and nursing students feel today alongside the impending alarm they have for life in clinical practice: 20% of medical and nursing students in the UK are considering quitting their undergraduate studies 57% of medical and nursing students in the UK report they are worried about their mental well-being 64% of medical and nursing students in the UK believe they will suffer from clinician burnout 75% of medical and nursing students in the UK are concerned about healthcare staff shortages and the impact this would have on them in their future role Anjola Awe, a third-year medical student at King’s College London, said: “I have always known that I wanted to be a doctor; I’ve dedicated my life to getting to this stage. Honestly, the findings and themes in the report are not at all surprising to me or my peers; we know only too well the reality of what being a frontline healthcare professional means today. We need to be vocal about the pressure we are under, the state of our mental health, and the volume of our academic workload.” As of June this year, there were more than 125,000 vacancies in secondary care in England, and over 10% of all nursing posts remain unfilled. 1 Despite the NHS treating more patients than before the pandemic, the waiting list for NHS treatment currently stands at a record 7.75 million. 2 Against this backdrop, it is unsurprising that medical and nursing students in the UK are concerned about the challenges they will face in the future. Dr Philip Xiu, a general practitioner and educational lead who supports medical students and junior doctors in Leeds, West Yorkshire, said: “As an educator, I see daily how vital it is we address students’ well-being concerns. Doubling enrolment won’t resolve looming workforce shortages if issues impeding student wellness go unresolved. We must equip them with critical thinking to aid sound clinical decisions, and partnership skills to involve patients meaningfully in care. By listening and responding to students’ needs, we can graduate resilient, empowered clinicians ready to elevate healthcare.” The Clinician of the Future 2023: Education Edition also identifies key insights into both the excitement and reservation towards technology and generative AI student curriculum. In the UK, 53% of medical and nursing students say they are excited at the potential of AI; however, 54% report they are worried about its use to support education. Furthermore, 74% admit to feeling overwhelmed by the amount of information they are expected to retain, with 44% now using generative AI, such as ChatGPT and Bard. Jan Herzhoff, President of Elsevier Health, said: “It’s clear that healthcare across the globe is facing unprecedented pressures, and that the next generation of medical and nursing students are anxious about their future. Whether through the use of technology or engaging learning resources, we must support students with new and innovative approaches to enable them to achieve their potential. However, the issues raised in this report can’t be tackled in isolation; it is essential that the whole healthcare community comes together to ensure a sustainable pipeline of healthcare professionals.” The Clinician of the Future 2023: Education Edition is the third edition published as part of Elsevier Health’s Clinician of the Future program, serving as the global health ecosystem’s leading pulse on the changes and challenges facing the doctors and nurses of today and tomorrow. For the full Clinician of the Future 2023: Education Edition, which includes robust data on global student attitudes toward health education, the future of healthcare, as well as the perspectives of instructors and more, click here. ### References: The British Medical Association. NHS medical staffing data analysis, The British Medical Association. Available at: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/workforce/nhs-medical-staffing-data-analysis (Accessed: 18 October 2023). The British Medical Association. NHS backlog data analysis, The British Medical Association. Available at: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/pressures/nhs-backlog-data-analysis (Accessed: 18 October 2023). Notes to editors: Research Methodology The Clinician of the Future 2023: Education Edition presents the results of a global survey of 2,212 students and two roundtable sessions with key opinion leaders in faculty in the US and UK. The aim is to gain a deep understanding of students’ experiences today and their expectations of the future in healthcare, as well as the perspectives of those instructing them. Elsevier Health’s commitments In addition to the Clinician of the Future 2023: Education Edition, we are committed to the following: Community Advisor Programmes of Osmosis: Providing elements of mentorship and connection to clinician communities Campus visits and feedback from students: Listening and learning through student feedback on how they are approaching their education challenges Year of the Zebra: An initiative to increase awareness of rare diseases and the benefits of patient care Hackathons: Providing clinical challenges for students in North America to advance their clinical education. Hosting webinars on resilience and depression in healthcare, as well as developing podcast episodes relevant to healthcare challenges Continued internships for medical and nursing students Supporting scholarships for minority students through the Elsevier Foundation About Elsevier Health For more than 140 years, Elsevier has supported the work of researchers and healthcare professionals by providing current, evidence-based information, that can help empower students and clinicians to provide the best healthcare possible. Growing from our roots, Elsevier Health applies innovation, facilitates insights, and helps drive more informed decision-making for our customers across global health. We support health providers by providing accessible, trusted evidence-based information to take on the infodemic; prepare more future health professionals with effective tools and resources; provide insights that help clinicians improve patient outcomes; deliver healthcare that is truly inclusive; and supports a more personalized and localized healthcare experience. Diversity and inclusion are the foundation of our innovation, and our teams are committed to creating education and practice solutions that reflect the diversity of our world. Elsevier is helping lay the groundwork for more equitable healthcare worldwide; We bring the same rigor to our digital information solutions as we do to our publishing, allowing us to offer knowledge and valuable analytics that help our users make breakthroughs and drive progress for the benefit of every patient. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses. Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet and Cell; 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details Dan DiPietro-James Global Media Relations Director dan.james@elsevier.com Chris West Senior Manager, Global Communications c.west1@elsevier.com Company Website https://www.elsevier.com/

October 30, 2023 03:45 AM Eastern Daylight Time

Visit by His Majesty’s Trade Commissioner for North America to Electric Works, Fort Wayne, Indiana

Ancora L&G

Ancora L&G, yesterday welcomed Emma Wade-Smith OBE to Electric Works, in her capacity as His Majesty’s Trade Commissioner for North America and HM Consul General New York, during an official visit to Indiana. During the visit, the Trade Commissioner also met with representatives from the Indiana Economic Development Corporation, the City of Fort Wayne, NEI, and Greater Fort Wayne Inc., as well as regional business leaders. Electric Works, the former site of the General Electric campus, was developed by a public-private partnership of Ancora, Biggs Group, and Weigand Construction, together with the City of Fort Wayne, Allen County, and the State of Indiana. Construction started in 2020, with a strategic focus on urban redevelopment and a commitment to community revitalization. At its peak, the site on which Electric Works stands—an 18-building industrial complex—employed about a third of Fort Wayne's workforce and for over eight decades, produced electric motors, transformers and other critical components. Following decades of deindustrialization and waves of job cuts, the campus closed in 2015. The West Campus – Phase 1 – of Electric Works is a $286 million mixed-use development of 740,000 sq. ft.; the largest historic adaptive reuse project in the State of Indiana. West Campus includes a mix of uses including creative office, retail, entertainment, healthcare, innovation and co-working, a public market and local produce food hall, education, as well as public and event spaces. Building on the success of the West Campus, Phase 2 of Electric Works is planned as a $143.4 million mixed-use development of market rate housing, affordable and low-income housing - including units targeted to 55+ age bracket; over 10,000 sq. ft. new model early childhood learning center in partnership with a university to train new teachers; commercial space; a health/wellness center and parking. As part of the visit, there was a tour of Amp Lab, a new public education model for up to 400 11th and 12th grade students, which provides a STEAM (Science Technology Engineering Arts and Mathematics) curriculum and immersive learning and internship opportunities, in partnership with Electric Works’ businesses. Amp Lab has supported 800 pupils so far from the Fort Wayne area. Jeff Kingsbury, Chief Connectivity Officer, Ancora L&G, said, “To achieve inclusive growth, innovation districts like Electric Works prioritize talent attraction, development, and retention. Affordable housing and education are important to talent, and are therefore critical economic development issues in both the U.S. and the U.K. We discussed these shared challenges and opportunities with the Trade Commissioner during her visit to the campus and appreciate the time she spent with us and her interest and support for the community’s vision of Electric Works.” Emma Wade Smith OBE, HM Trade Commissioner for North America and HM Consul General New York, said: “ We signed the UK’s first State-level trade and economic cooperation agreement with Indiana in May 2022. At the heart of our ambitions is increasing trade and spurring more inclusive and sustainable economic growth, where opportunities and meaningful jobs are accessible to people across our communities. The Ancora Electric Works development is a terrific example of how UK-US collaboration can enable the revitalisation of such iconic and historic industrial sites. The transformation of this facility has captured the imagination of the community, by promoting access to opportunities that support our shared priorities in innovation, STEAM (science, technology, engineering, arts and math) and sustainability.” Riley Johnson, Director of Amp Lab, said, “Amp Lab is a unique learning environment built for students of diverse backgrounds to gain real-world experience. We were honored to host Trade Commissioner Emma Wade-Smith and thrilled to be recognized as a model of innovative and agile education.” ENDS Notes to editors Ancora L&G A joint venture between U.S.-based science and technology real estate developer Ancora and Legal & General Capital ( LGC ), the investment arm of global asset manager Legal & General, Ancora L&G acquires and develops real estate to serve high-growth science, technology, and innovation tenants in partnership with and proximate to leading U.S. anchor institutions. Ancora was founded in 2019 by Josh Parker with co-founders John Philipchuck and Jeff Kingsbury. Currently capitalized at $500 million with plans to expand to $4 billion, Ancora L&G currently has projects in Atlanta, Georgia (Georgia Tech); Providence, Rhode Island (Brown University); and New Haven, Connecticut (Yale University). Legal & General Capital Legal & General Capital (LGC) is Legal & General Group’s alternative asset platform, creating assets for Legal & General Retirement and third-party clients in order to achieve improved risk-adjusted returns for our shareholders. LGC has built its market leading capabilities in a range of alternative assets, delivering depth of resource, track record and intellectual property. Investing in the real economy and creating alternative assets that deliver a tangible societal impact, its purpose is to invest society’s capital for society’s benefit. L&G has invested around £30 billion ($37 million) in levelling-up regional UK economies and has strong track record in investing in technology and life sciences. LGC’s investments include residential property; specialist commercial real estate; clean energy; alternative credit; and venture capital. As LGC’s capability to create alternative assets continues to grow, it will not only continue to grow its balance sheet of alternative assets but also create alternative assets for third party investors. Legal & General Group Established in 1836, Legal & General is one of the UK’s leading financial services groups and a major global investor, with international businesses in the U.S., Europe, Middle East, and Asia. With over £1.24 trillion in total assets under management, we are the UK’s largest investment manager for corporate pension plans and a UK market leader in pension risk transfer, life insurance, workplace pensions and retirement income. Legal & General Group currently manages $1.4 trillion of assets globally and is increasing its presence in the U.S. for both equity and debt vehicles. The year-old Ancora L&G joint venture builds on the successful track record of Ancora’s team and the investing record of LGC in the UK, including over $5 billion currently committed to science and technology development projects at Oxford, Manchester, and other leading universities in the UK. Contact Details Meir Kahtan Public Relations, LLC (MKPR) Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Director of External Engagement, Legal & General Margrit Williams +1 347-387-7555 margrit.williams@landg.com

October 27, 2023 04:52 PM Eastern Daylight Time

Image

Hainan Boao Hope City Pioneering Unique Medical Policies and Driving Collaboration with Denmark's Biopharmaceutical Industry

Hainan Boao Lecheng International Medical Tourism Pilot Zone

HAINAN, CHINA - Media OutReach - 28 October 2023 - From 12 to 13 October, a delegation from Hainan Province, organised by the Hainan Provincial Government, visited Denmark for a series business events to attract investment and talents. During the events, the first and currently the only special medical zone in China, the Boao Lecheng International Medical Tourism Pilot Zone（Boao Hope City） was featured at the Hainan Free Trade Port Lecheng Denmark Promotion Conference, the delegation also took the opportunity to visit some local pharmaceutical companies and relevant institutions in Denmark, sharing opportunities and showcasing the aspirations to achieve win-win cooperation. Representatives and officials from over 30 renowned international pharmaceutical and medical device companies, such as ALK from Denmark, the Nordic Life Science Partners ApS (NLSP), and the Danish Life Science Cluster, gathered to explore potential collaborations and shared goals in the medical sector between Denmark and the Hainan Free Trade Port at the Promotion Event. The discussions primarily focused on the emerging opportunities and future prospects for cooperation, as well as the specific areas of collaboration within the biopharmaceutical industry. Fruitful conversations were held with the Hainan delegation, fostering meaningful exchanges. The upcoming 2 nd Boao International Conference on Real World Studies of Medical Products, scheduled for the end of October this year, also captured the interest of the attendees. It is estimated that approximately 800 experts, scholars, and executives from domestic and international pharmaceutical regulatory agencies, research institutes, and pharmaceutical companies will participate in the conference. During the event, the Boao Lecheng International Medical Tourism Pilot Zone Administration, the Danish Life Science Cluster, and NLSP came together to sign a strategic cooperation agreement. The agreement aims to foster deeper collaboration in various areas such as healthcare, chronic disease prevention and management, telemedicine, digital health, as well as the introduction of innovative drugs and medical devices. On the following day, the Boao Lecheng International Medical Tourism Pilot Zone Administration, along with representatives from medical institutions in the zone, continued their investment and business activities in Denmark. They actively engaged in exchanges and established connections with Healthcare Denmark, ALK, and other innovative pharmaceutical companies and relevant institutions in Denmark, with the aim of advancing cooperation in the biopharmaceutical industry. Officials from the Hainan Provincial Government acknowledged Denmark's global reputation in the healthcare sector and highlighted the open environment for foreign trade and unique medical policies offered by the Hainan Free Trade Port that could bring benefits to the Boao Hope City. As the benefits and advantages provided by the policies of the Hainan Free Trade Port are gradually becoming evident and accessible and the business environment improves, both Denmark and Hainan can capitalise on their respective strengths to explore substantial opportunities for cooperation in the medical sector. Representatives from Healthcare Denmark acknowledged the thriving development of the Hainan Free Trade Port, which presents multinational pharmaceutical companies with extensive growth prospects. They expressed their dedication to focusing on Hainan and the Boao Hope City, making the most of the distinctive policy benefits and strategic location offered by the Hainan Free Trade Port and the Boao Hope City. They also emphasised their intention to leverage their institutional connections to high-quality medical resources in Denmark to foster deeper cooperation and explore opportunities for development. Hainan the Boao Hope City（ http://en.lecityhn.com/ ） has capitalised on the benefits of the "pilot zone" policy and the collaboration with international pharmaceutical and medical device companies. It has forged strong partnerships with more than 170 companies in the pharmaceutical and medical device sectors from over 20 countries and regions. This collaborative effort has facilitated the introduction of over 350 urgently needed imported medical devices for clinical use. Additionally, leveraging the Boao Hope City's real-world evidence-based clinical evaluation, twelve products have successfully obtained registration in the domestic market. As a result, the Boao Hope City has emerged as the primary gateway for international innovative pharmaceutical and medical devices to expedite their entry into the Chinese market. Moving forward, the Boao Hope City will further enhance its commitment to openness and cooperation. It will strengthen collaborations with global pharmaceutical companies and exceptional expert teams, constantly introducing high-quality medical resources and advanced pharmaceuticals into the technologies from around the world. The aim is to expedite the entry of international innovative Chinese market, ultimately benefiting the general public. These efforts will also contribute to positioning the Hainan Free Trade Port as a leading hub for medical innovation in China. Contact Details Chen Xi +86 898 6283 0087 chenxi@lecityhn.com

October 27, 2023 01:58 PM Eastern Daylight Time

Video Image